제14회 국제의약품·바이오산업전 KOREA PHARM & BIO 2024
BOOTH : HALL7 - 7E101
포장용기 적합성
용출물시험 / 침출물 시험
2019 의약품용기 및 포장적합성평가 가이드라인
Extractables study / Leachables study
USP1663 / USP1664
USP665 / USP1665
∘ 일 시 : 2024년 4월 23~26일(화~금)
∘ 장 소 : 일산 킨텍스 제2 전시장 (HALL 7)
(BOOTH 7E101)
∘ 주 최 : INTERTEK & (주)큐비디
제14회 국제의약품·바이오산업전 KOREA PHARM & BIO 2024
날짜 | 시간 | 장소 | 세미나명 |
| 4월 23일 (화) | 11:30-12:30 | 2전시장 7홀 현장세미나실 C | 용기적합성 (Extractables and Leachables) 워크샵 |
| 4월 34일 (수) | 11:30-12:30 | 2전시장 7홀 현장세미나실 C | 용기적합성 (Extractables and Leachables) 워크샵 |
| 4월 25일 (목) | 11:00-12:00 | 2전시장 7홀 현장세미나실 C | 용기적합성 (Extractables and Leachables) 워크샵 - Targeted and Unanticipated Leachables |
| 4월 26일 (금) | 13:00-14:00 | 2전시장 7홀 현장세미나실 C | 용기적합성 (Extractables and Leachables) 워크샵 |
A profile of extractable components must be obtained, via controlled extractables studies (CES), in order to identify potential sources of leachables such as antioxidants, plasticizers, dyes and metal catalysts. As pharmaceutical packaging, drug delivery systems and implantable medical devices can be extremely complex, with mixtures of plastic, polymer, rubber or glass materials, printed surfaces and coatings all utilized, it is critical that E/L studies are designed specifically for your drug product and the container materials so that the risks associated with leachable impurities can be assessed.
Our scientists conduct extractables and leachables studies in accordance with regional guidance, Good Manufacturing Practice (GMP) PQRI recommendation, BPOG, United States Pharmacopeia (USP) requirements (including USP chapters <1663>, <1664>, <1664.1>, <665> and ,1665.), and awareness of FDA guidelines. As an initial step, we aim to gather all information about your packaging system in order to obtain a strong impression of potential sources of extractables or leachables. The combination of our experience in method development for controlled extractables studies, coupled with our vast knowledge of leachable compounds, mean that we can anticipate and identify potential sources of risk through strategic screening studies.
We provide leachables method validation compliant to Good Manufacturing Practice (GMP) for use in storage and stability programs and can support a wide range of closure or drug delivery systems such as pre-filled syringes, large volume parenteral products, orally inhaled and nasal drug products (OINDP), single use and disposable medical equipment, printed packaging and bioprocessing equipment. Leachables associated with drug delivery systems, implantable medical devices and other devices such as e-cigarettes are also assessed.
Our analytical teams can determine both organic and inorganic contaminants through the application of a range of instrumentation including liquid chromatography (HPLC) liquid chromatography-mass spectrometry (LC-MS(MS)), gas chromatography (GC), gas chromatography-mass spectrometry (GC-MS(MS)), and inductively coupled plasma spectroscopy (ICP, ICP-MS), dependent on the analysis.
With specialists in glass delamination studies, we provide a range of solutions that help mitigate the risks associated glass delamination and leaching of metal ions /elemental impurities from glass into drug products for molded bottles, containers, vials or prefillable syringes.
Comprehensive evaluation and safety assessment review of laboratory E/L study data is performed by our in-house toxicologist consultants in order to identify and address potential risks and to assist with comprehensive impurity testing, whilst identifying any gaps in your existing data packages. We also provide recommendations and support for preparation of very low-risk data packages related to E/L testing.
Extractable Leachables Specialists
Our experts have over 30 years’ experience in specialised analytical and toxicology assessment for extractables and leachables, and this is reinforced by our knowledge of polymer, plastic and packaging materials, allowing us to identify components from the most complex polymer formulation including adhesives, additives and stabilizer ingredients and their degradation products. Our consultants provide a first-class evaluation and assessment of existing E/L data gaps, and through strategic screening or quantitative studies, we offer the right study for your product. Intertek also provides recommendations and support for preparation of very low risk data packages related to E/L testing.
